Accounts Payable (Quarterly) Chart

View Accounts Payable (Quarterly) for AMGN.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Accounts Payable (Quarterly) Chart
Start Trial

Historical Accounts Payable (Quarterly) Data

View and export this data back to 1998. Start Trial.
Date Value
March 31, 2026 2.935B
December 31, 2025 2.367B
September 30, 2025 2.838B
June 30, 2025 3.01B
March 31, 2025 2.406B
December 31, 2024 1.908B
September 30, 2024 2.147B
June 30, 2024 2.267B
March 31, 2024 1.628B
December 31, 2023 1.59B
September 30, 2023 1.358B
June 30, 2023 1.212B
March 31, 2023 1.32B
December 31, 2022 1.572B
September 30, 2022 1.204B
June 30, 2022 1.256B
March 31, 2022 1.403B
December 31, 2021 1.366B
September 30, 2021 1.171B
June 30, 2021 1.277B
March 31, 2021 1.396B
December 31, 2020 1.421B
September 30, 2020 1.161B
June 30, 2020 1.15B
March 31, 2020 1.338B
Date Value
December 31, 2019 1.371B
September 30, 2019 1.005B
June 30, 2019 1.001B
March 31, 2019 1.091B
December 31, 2018 1.207B
September 30, 2018 1.042B
June 30, 2018 1.026B
March 31, 2018 1.089B
December 31, 2017 1.352B
September 30, 2017 879.00M
June 30, 2017 883.00M
March 31, 2017 902.00M
December 31, 2016 917.00M
September 30, 2016 825.00M
June 30, 2016 870.00M
March 31, 2016 818.00M
December 31, 2015 965.00M
September 30, 2015 1.067B
June 30, 2015 934.00M
March 31, 2015 888.00M
December 31, 2014 1.212B
September 30, 2014 955.00M
June 30, 2014 982.00M
March 31, 2014 949.00M
December 31, 2013 787.00M

Accounts Payable Definition

Accounting terminology for money that a company owes to vendors for services or products that it purchased on credit. Accounts payable appear on the balance sheet as a current liability.

Read full definition.

Accounts Payable (Quarterly) Range, Past 5 Years

View Accounts Payable (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Accounts Payable (Quarterly) Benchmarks

View Accounts Payable (Quarterly) Benchmarks
Start Trial
Biogen, Inc. 358.50M
Gilead Sciences, Inc. 645.00M
Regeneron Pharmaceuticals, Inc. 1.027B
AbbVie, Inc. 33.61B
Viridian Therapeutics, Inc. 13.31M